ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
06/10/2026
Back to search
Official data from USPTO
HEPNET
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
19
Latest update
06/11/2026
Classification
Registered
Trademark type
Combined
Nice classes
5, 9, 40, 42
Filing date
09/18/2023
Registration date
01/21/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/21/2025
Last transaction
06/11/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
3
Owner type
84
Owner location
LONDON, GB
Examiner
ARRISON, RACHEL MARIE
Law office
L60
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of a square. The word "HEPNET" appears inside of the square in stylized font. A diagonal line is between the letters "P" and "N".
Holders and representatives
Holders
TANGRAM THERAPEUTICS PLC
E-THERAPEUTICS PLC
Representatives
Anna King BANNER & WITCOFF, LTD.
Technical classification
Nice Classes
Class 5Class 9Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of pharmaceutical preparations targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticalsnucleic acid-based drugs (NABDs); drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticalsnucleic acid-based drugs (NABDs)all for targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blockingsilencinginhibiting gene expressionfor use in targeting mRNA and triggering its degradation; short interfering RNA-based (siRNA) medicines and pharmaceuticals for use in targeting genes and blockingsilencinginhibiting gene expressionfor use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for use in targeting genes and blockingsilencinginhibiting gene expressionfor use in targeting mRNA and triggering its degradation; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation
Class 9
Downloadable and recorded computer software for use in the field of pharmaceuticalsmedicines and drug discoveryfor evaluatinganalysinginterpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded artificial intelligence and machine learning software for use in the field of pharmaceuticalsmedicines and drug discoveryfor evaluatinganalysinginterpreting information contained in databases to identify new biological targets and gene-disease associations; electronic databases for use in the field of pharmaceuticalsmedicines and drug discoverydatabases containing information relating to potential biological drug targets and gene-disease associations recorded on computer media; downloadable and recorded computer platform software for use in the field of pharmaceuticalsmedicines and drug discoveryfor evaluatinganalysinginterpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software platforms for use in the field of pharmaceuticalsmedicines and drug discoveryfor evaluatinganalysinginterpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software enabling the searching and retrieval of data relating to pharmaceuticalsmedicines and drug discovery; downloadable and recorded software for the analysis of data relating to pharmaceuticalsmedicines and drug discovery; downloadable and recorded search engine software for use in the field of pharmaceuticalsmedicines and drug discovery; downloadable and recorded search engine software for the searchingretrievalindexing and analysis of data relating to pharmaceuticalsmedicines and drug discovery.
Class 40
Custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blockingsilencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of informationadvice and consultancy services relating to all of the aforesaid
Class 42
Scientific research and development in the field of targeting genes and blockingsilencing or inhibiting gene expression; scientificpharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientificpharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blockingsilencing or inhibiting gene expression; scientificpharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicinesnucleic acid-based drugs (NABDs) for blocking gene expressionnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionandpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blockingsilencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicinesnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; scientific and technical testing and data analysis in relation to pharmaceuticals and medicines; scientific and technical testing and data analysis in relation to RNAi-based medicines; scientific and technical testing and data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blockingsilencing or inhibiting gene expression; scientific and technical testing and data analysis in relation to short interfering RNA (siRNA) medicinesnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; designdevelopmentcreation and maintenance of computer platforms and computer software for use in the field of pharmaceuticalsmedicines and drug discovery; designdevelopmentcreation and maintenance of computer platforms and computer software enabling the searching and retrieval of data relating to pharmaceuticalsmedicines and drug discovery; designdevelopmentcreation and maintenance of computer platforms and computer software for the analysis of data relating to pharmaceuticalsmedicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for use in the field of pharmaceuticalsmedicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for the searchingretrievalindexing and analysis of data relating to pharmaceuticalsmedicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticalsmedicines and drug discoveryfor modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparations; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticalsmedicinesdrug discoveryfor generating RNAi-based medicines and pharmaceuticalsshort interfering RNA (siRNA) medicinesnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design and development of computer-simulated models for use in the field of pharmaceuticalsmedicines and drug discovery; design of and providing temporary use of non-downloadable computer software for use in the field of pharmaceuticalsmedicines and drug discoveryfor evaluatinganalysinginterpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services featuring software using artificial intelligence and machine learning software and databases in the field of pharmaceuticalsmedicines and drug discoveryfor evaluatinganalysinginterpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the field of pharmaceuticalsmedicines and drug discoveryfor modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating RNAi-based medicines and pharmaceuticalsnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of informationadvice and consultancy services relating to all of the aforesaid
Publications
History of USPTO decisions and trademark events.
19 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/21/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
01/21/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/03/2024
PUBO
PUBLISHED FOR OPPOSITION
12/03/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/27/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/18/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/20/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/20/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/20/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
08/06/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
08/06/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/22/2024
GNRT
NON-FINAL ACTION E-MAILED
05/22/2024
CNRT
NON-FINAL ACTION WRITTEN
05/22/2024
DOCK
ASSIGNED TO EXAMINER
05/10/2024
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/05/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/04/2023
NWAP
NEW APPLICATION ENTERED
09/21/2023
Continuous trademark protection
Get notified about every new filing that threatens HEPNET or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.